Pulmonary Cell News Volume 9.19 | May 21 2020

TOP STORY

Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR-cMet Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion-Driven NSCLC

Ba/F3 cells and patient-derived cells/organoids/xenograft models harboring diverse EGFR exon 20 insertion driver mutations were used to characterize the antitumor mechanism of amivantamab. [Cancer Discov] Abstract

(Ranked by impact factor of the journal)

Expression of the SARS-CoV-2 ACE2 Receptor in the Human Airway Epithelium

Airway epithelium sampled by fiberoptic bronchoscopy of trachea, large airway epithelium and small airway epithelium of nonsmokers and smokers was analyzed for expression of ACE2 and other coronavirus infection-related genes. [‎Am J Respir Crit Care Med] Full Article

Dissecting the Cellular Specificity of Smoking Effects and Reconstructing Lineages in the Human Airway Epithelium

Knockout studies revealed that tuft-like cells were the likely progenitor of both pulmonary neuroendocrine cells and CFTR-rich ionocytes. [Nat Commun] Full Article

Cigarette Smoke Exposure and Inflammatory Signaling Increase the Expression of the SARS-CoV-2 Receptor ACE2 in the Respiratory Tract

Investigators demonstrated that angiotensin converting enzyme 2 (ACE2) was expressed in a subset of secretory cells in the respiratory tract. [Dev Cell] Abstract | Graphical Abstract

A Mammalian Wnt5a-Ror2-Vangl2 Axis Controls the Cytoskeleton and Confers Cellular Properties Required for Alveologenesis

Scientists found that the planar cell polarity pathway was required in alveolar epithelial cells and myofibroblasts for alveologenesis in mammals. [eLife] Full Article

Allele-Specific Prevention of Nonsense-Mediated Decay in Cystic Fibrosis Using Homology-Independent Genome Editing

In combination with protein modulators, genome editing significantly increased the potentiated channel activity of W1282X-CFTR in human bronchial epithelial cells. [Mol Ther Methods Clin Dev] Abstract | Graphical Abstract

Hydrodynamic Model of Directional Ciliary-Beat Organization in Human Airways

The authors showed on human bronchial epithelium reconstituted in vitro that the dynamics of ciliary-beat orientation was closely connected to hydrodynamic effects. [Sci Rep] Full Article

LUNG CANCER

Correction of the Tumor Suppressor Salvador Homolog-1 Deficiency in Tumors by Lycorine as a New Strategy in Lung Cancer Therapy

Researchers found that the small molecule lycorine notably increased SAV1 levels in lung cancer cells by inhibiting SAV1 degradation via a ubiquitin-lysosome system. [Cell Death Dis] Full Article

Glycine Metabolomic Changes Induced by Anticancer Agents in A549 Cells

Investigators showed all tested anticancer agents could alter glycine metabolism in A549 cells including inhibition of pyruvate metabolism and down-regulation of betaine aldehyde and 5′-phosphoribosylglycinamide. [Amino Acids] Abstract

Subscribe to one of our other 19 science newsletters such as Cancer Stem Cell News & Human Immunology News.

Immune Checkpoint Blockade in Oncogene-Driven Non-Small-Cell Lung Cancer

Given the growing role of immune checkpoint inhibitor (ICI) therapy in the treatment of lung cancer, oncogene-driven cancer has warranted further evaluation regarding ICI therapy. [Drugs] Abstract

Visit our reviews page to see a complete list of reviews in the pulmonary cell research field.

US Food and Drug Administration Approves Opdivo^® (Nivolumab) + Yervoy^® (Ipilimumab) as First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer Whose Tumors Express PD-L1≥1%

Bristol Myers Squibb announced that Opdivo 3 mg/kg plus Yervoy 1 mg/kg was approved by the FDA for the first-line treatment of adult patients with metastatic non-small cell lung cancer whose tumors express PD-L1 as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations. [Bristol Myers Squibb] Press Release

FDA Approves Genentech’s Tecentriq as a First-Line Monotherapy for Certain People with Metastatic Non-Small Cell Lung Cancer

Genentech announced that the FDA has approved Tecentriq^® as a first-line treatment for adults with metastatic non-small cell lung cancer. [Genentech] Press Release

Will Trump White House Tear Down Journal Paywalls? Many Anxiously Await a Decision

Scientific publishers, universities, librarians, and open-access advocates are waiting anxiously to see whether the Trump administration will end a long-standing policy and require that every scholarly article produced with US funding be made immediately free to all. [ScienceInsider] Editorial

Are Women Publishing Less during the Pandemic? Here’s What the Data Say

Early analyses suggest that female academics are posting fewer preprints and starting fewer research projects than their male peers. [Nature News] Editorial

In light of COVID-19, many conferences are being cancelled or postponed. As such:

We are suspending new event postings in our newsletters and on Twitter.
We will strive to keep our current event listings updated with event status.
We encourage you to visit event sites directly for updates.

Visit our events page to see a complete list of events in the community.

NEW Postdoctoral Associate – Lung Cancer Research (Yale University)

Associate Professor – Cell Biology (Dana-Farber Cancer Institute)

Postdoctoral Scientist – Lung Cancer Clinical Research (Instituto de Investigación Hospital)

Principal Scientist – Respiratory Inflammation Research (Amgen Inc.)

Junior Research Group Leader – Lung Cancer (Justus Liebig University Giessen)

Branch Chief – Integrative Tumor Epidemiology (NIH National Cancer Institute)

PhD Studentship – Organoid Engineering in Lung Diseases (Helmholtz Zentrum München German Research Center for Environmental Health)

Laboratory Manager – Lung Diseases (Helmholtz Zentrum München)

Postdoctoral Fellow – SARS-CoV-2 Lung Infection (Boston University)

Research Fellow – Respiratory Viruses (Queen’s University Belfast)

Research Associate – Cystic Fibrosis (Michigan State University)

Postdoctoral Fellowship – Lung Epithelium (Boston University)

Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Pulmonary Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here.